share_log

LadRx (NASDAQ:CYTR) Earns Hold Rating From Analysts at StockNews.com

LadRx (NASDAQ:CYTR) Earns Hold Rating From Analysts at StockNews.com

LADRX（納斯達克：賽特）在證券新聞網上獲得分析師的保持評級
kopsource ·  2022/12/27 02:02

StockNews.com began coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a research report released on Friday morning. The brokerage issued a hold rating on the stock.

斯托克新聞網在週五上午發佈的一份研究報告中開始報道LadRx(納斯達克：Cytr-Get Rating)的股票。該券商對該股發佈了持有評級。

LadRx Stock Up ∞

LadRx庫存∞

NASDAQ:CYTR opened at $0.09 on Friday. LadRx has a 1 year low of $0.05 and a 1 year high of $0.86. The business has a 50 day simple moving average of $0.10 and a 200-day simple moving average of $0.13.

納斯達克：Cytr上週五開盤報0.09美元。LadRx的一年低點為0.05美元，一年高位為0.86美元。該業務的50日簡單移動均線切入位在0.10美元，200日簡單移動均線切入位在0.13美元。

Get
到達
LadRx
LadRx
alerts:
警報：

About LadRx

關於LadRx

(Get Rating)

(獲取評級)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
LadRx公司是一家生物製藥研發公司，從事新型抗癌候選藥物的發現、研究和臨床開發。它專注於開發Linker激活藥物釋放(LADR)技術平臺，這是一個發現引擎，可以幫助創建一條抗癌分子的管道，在避免不可接受的全身毒性的同時，將高效藥物直接輸送到腫瘤。

See Also

另請參閱

  • Get a free copy of the StockNews.com research report on LadRx (CYTR)
  • Three Healthcare Penny Stocks to Watch In The New Year
  • Southwest Airlines Stock, There is a Lot to Love
  • MarketBeat: Week in Review 12/19 – 12/23
  • These Steelmakers Deserve A Place On Your 2023 Watch List
  • Inflation Cools, Where Does The S&P 500 Go Now
  • 免費獲取StockNews.com關於LadRx的研究報告(Cytr)
  • 新年值得關注的三隻醫療保健便士股
  • 西南航空公司股票，有很多值得愛的東西
  • MarketBeat：回顧一週12/19-12/23
  • 這些鋼鐵制造商理應在2023年觀察名單上佔有一席之地
  • 通脹降溫，標普500指數何去何從

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.

接收LadRx Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對LadRx和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論